PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

NCT05239039 ·Status: COMPLETED ·Phase: PHASE3

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT06295692 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

NCT03135548 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

NCT01988103 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)

NCT06231381 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

NCT02595970 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis

NCT05565560 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

NCT02533375 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

NCT03924427 ·Status: COMPLETED ·Phase: PHASE3

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

NCT05215561 ·Status: COMPLETED

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

NCT03051217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

NCT02343744 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

NCT02931838 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

NCT06176508 ·Status: RECRUITING ·Phase: PHASE2

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768 ·Status: COMPLETED ·Phase: PHASE3

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

NCT03782792 ·Status: COMPLETED ·Phase: PHASE2

A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis

NCT06952465 ·Status: ACTIVE_NOT_RECRUITING

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950 ·Status: COMPLETED ·Phase: PHASE2

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02207231 ·Status: COMPLETED ·Phase: PHASE3

Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

NCT06039189 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis

NCT00809614 ·Status: COMPLETED ·Phase: PHASE2

HB0034 in Patients With Generalized Pustular Psoriasis (GPP)

NCT05512598 ·Status: COMPLETED ·Phase: PHASE1

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

NCT00669916 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

NCT01519089 ·Status: COMPLETED ·Phase: PHASE3